Filing Flows › Northwest Biotherapeutics (NWBO) › Q1 2026 › vs Q4 2025
Northwest Biotherapeutics (NWBO) Q1 2026 vs Q4 2025 (quarter over quarter)
Northwest Biotherapeutics's revenue fell $178K (-26%) from $672K in Q4 2025 to $494K in Q1 2026.
Northwest Biotherapeutics, Q1 2026: revenue $494K (+32% year over year), net earnings $3.1M, operating cash flow −$12.5M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $494K | $672K | −$178K | -26% |
| Other income, net | $14.0M | −$108M | $122M | — |
| Costs & expenses | $14.5M | $122M | −$108M | -88% |
| Operating costs | $11.4M | $14.2M | −$2.8M | -20% |
| Net earnings | $3.1M | −$122M | $125M | — |
| Research & development | $4.9M | $5.6M | −$696K | -13% |
| General & admin | $6.5M | $8.6M | −$2.1M | -24% |
| Operating cash sources | $16.7M | −$106M | $123M | — |
| Depreciation & amortization | $771K | $728K | $43K | +6% |
| Share-based compensation | $288K | $185K | $103K | +56% |
| Cash used in operations | $12.5M | $14.8M | −$2.3M | -15% |
| Working capital & other | $16.7M | −$106M | $123M | — |
Questions
How much did Northwest Biotherapeutics's revenue grow quarter over quarter in Q1 2026?
Northwest Biotherapeutics's revenue fell $178K (-26%) from $672K in Q4 2025 to $494K in Q1 2026.